C4 Therapeutics Inc. (CCCC)
1.25
0.15 (13.64%)
At close: Apr 17, 2025, 3:59 PM
1.24
-0.80%
After-hours: Apr 17, 2025, 07:49 PM EDT
13.64% (1D)
| Bid | 1.1 |
| Market Cap | 88.74M |
| Revenue (ttm) | 35.58M |
| Net Income (ttm) | -105.32M |
| EPS (ttm) | -1.52 |
| PE Ratio (ttm) | -0.82 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 1.26 |
| Volume | 1,766,651 |
| Avg. Volume (20D) | 1,355,087 |
| Open | 1.10 |
| Previous Close | 1.10 |
| Day's Range | 1.09 - 1.30 |
| 52-Week Range | 1.08 - 7.66 |
| Beta | 3.12 |
About CCCC
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma an...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 2, 2020
Employees 110
Stock Exchange NASDAQ
Ticker Symbol CCCC
Website https://www.c4therapeutics.com
Analyst Forecast
According to 4 analyst ratings, the average rating for CCCC stock is "Buy." The 12-month stock price forecast is $13, which is an increase of 940.00% from the latest price.
Stock ForecastsNext Earnings Release
C4 Therapeutics Inc. is scheduled to release its earnings on May 7, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
7 months ago
+13.79%
C4 Therapeutics shares are trading higher after th...
Unlock content with
Pro Subscription
